4 June 2011 in Laser Physics
Significant apoptotic effect in Hep2c cell line has been investigated, when diode laser (λ = 635 nm, red) are used as a source of illumination and initiation of photodynamic action. The optimal uptake time of Photofrin® for Hep2c cell line was investigated by means of spectrophotometric measurement. Quantification of the live cell population was determined by means of neutral red assay (NRA). The spectrometry measurements showed that after 46 h incubation, the maximal cellular uptake of Photofrin® was achieved and photocytotoxic assay showed that light dose of 120 J/cm2 give effective PDT outcome for Hep2c cell line incubated with 85 μg/ml of Photofrin®. No significant phototoxic and cytotoxic effects on Hep2c cells were observed due to light doses or photosensitize, when studied independently of each other and Photofrin® showed good anti tumor effects.
1 December 2020 in Photodiagnosis and Photodynamic Therapy
13 December 2018 in Laser Physics
Nowadays combination of various therapeutic modalities is an attractive strategy in cancer treatment. In order to develop more efficient combinational therapy, we investigated the effect of Vitamin K3 (menadione) to enhance the cytotoxic action of chemo-photodynamic therapy against Rhabdomyosarcoma (RD) cell line, using Photosense as a photosensitizer and different chemo therapeutic agents. RD cell line was cultured for the evaluation of efficacy in the presence and absence of vitamin K3 with other chemotherapeutic agents. Diode laser ( λ = 635 nm) was used for initializing the photodynamic action of Photosense mediated photodynamic therapy (PDT). Cytotoxicity was measured by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Pre-treatment for 24 h to RD cells with K3 significantly potentiates sensitivity of chemotherapy. Chemotherapeutic agents and K3 showed significant killing effect when combined with PDT, at very low doses. These results suggest that this procedure could be the basis for an improved chemo-PDT protocol for cancer control.